Podocyte mitosis – A catastrophe

Current Molecular Medicine

Volumn 13, Issue 1, 2013, Pages 13-23

  Lasagni, L ^a   Lazzeri, E ^a   Shankland, S J ^b   Anders, H J ^c   Romagnani, P ^a,d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Actin cytoskeleton; Foot process; Glomerulosclerosis; Mitotic catastrophe; Podocyte; Renal progenitor

Indexed keywords

ALPHA ACTININ 4; INTEGRIN LINKED KINASE; NEPHRIN; PODOCALYXIN; PODOCIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; ACTIN;

ACTIN FILAMENT; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL DAMAGE; CELL DIVISION; CELL MIGRATION; CHROMOSOME SEGREGATION; DNA REPLICATION; DNA SYNTHESIS; GENE DELETION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HUMAN; HYPERTROPHY; KIDNEY DISEASE; MITOSIS; NONHUMAN; PROTEIN ANALYSIS; PROTEINURIA; ANIMAL; CELL CYCLE; CELL DIFFERENTIATION; CYTOLOGY; CYTOSKELETON; GENETICS; GLOMERULUS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PODOCYTE; REVIEW; STEM CELL;

ACTINS; ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; CYTOSKELETON; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MITOSIS; PODOCYTES; STEM CELLS;

EID: 84878425128     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652413804486250     Document Type: Article

References (112)

1. Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 2005; 67: 404-419.
2. Wharram BL, Goyal M, Wiggins JE, et al. Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005; 16: 2941-2952.
3. Kretzler M. Role of podocytes in focal sclerosis: Defining the point of no return. J Am Soc Nephrol 2005; 16: 2830-2832.
4. Kim YH, Goyal M, Kurnit D, et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN treated rat. Kidney Int 2001; 60: 957-968.
5. Wiggins RC. The spectrum of podocytopathies: A unifying view of glomerular diseases. Kidney Int 2007; 71: 1205-1214.
6. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
7. Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: A reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2007; 2: 529-542.
8. Greka A, Mundel P. Cell biology and pathology of podocytes. Annu Rev Physiol 2012; 74: 299-323.
9. Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001; 108: 1583-1587.
10. Huang TW, Langlois JC. Podoendin. A new cell surface protein of the podocyte and endothelium. J Exp Med 1985; 162: 245-267.
11. Takeda T, McQuistan T, Orlando RA, Farquhar MG. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J Clin Invest 2001; 108: 289-301.
12. Orlando RA, Takeda T, Zak B, et al. The glomerular epithelial cell anti-adhesin, podocalyxin, associates with the actin cytoskeleton through interactions with ezrin. J Am Soc Nephrol 2001; 12: 1589-1598.
13. Wharram BL, Goyal M, Gillespie PJ, et al. Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate. J Clin Invest 2000; 106: 1281-1290.
14. Blattner Sm. Integrin-linked kinase in renal disease: connecting cell-matrix interaction to the cytoskeleton. Curr Opin Nephrol Hypertens 2005; 14: 404-410.
15. Yuan H, Takeuchi E, Salant DJ. Podocyte slit-diaphragm protein nephrin is linked to the actin cytoskeleton. Am J Physiol Renal Physiol 2002; 282: F585-591.
16. Lehtonen S, Zhao F, Lehtonen E. CD2-associated protein directly interacts with the actin cytoskeleton. Am J Physiol Renal Physiol 2002; 283: F734-743.
17. Lynch DK, Winata SC, Lyons RJ, et al. A Cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton. J Biol Chem 2003; 278: 21805-21813.
18. Hutchings NJ, Clarkson N, Chalkley R, Barclay AN, Brown MH. Linking the T cell surface protein CD2 to the actincapping protein CAPZ via CMS and CIN85. J Biol Chem 2003; 278: 22396-22403.
19. Huber TB, Hartleben B, Kim J, et al. Nephrin and CD2AP Associate with Phosphoinositide 3-OH Kinase and Stimulate AKT-Dependent Signaling. Mol Cell Biol 2003; 23: 4917-4928.
20. Wartiovaara J. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest 2004; 114: 1475-1483.
21. Schwarz K, Simons M, Reiser J, et al. Podocin, a raftassociated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001; 108: 1621-1629.
22. Huber TB, Kottgen M, Schilling B, Walz G, Benzing T. Interaction with podocin facilitates nephrin signaling. J Biol Chem 2001; 276: 41543-41546.
23. Huber TB, Schermer B, Muller RU, et al. Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels. Proc Natl Acad Sci USA 2006; 103: 17079-17086.
24. Huber TB, Schermer B, Benzing T. Podocin organizes ion channel-lipid supercomplexes: implications for mechanosensation at the slit diaphragm. Nephron Exp Nephrol 2007; 106: e27-31.
25. Chen S, He FF, Wang H, et al. Calcium entry via TRPC6 mediates albumin overload-induced endoplasmic reticulum stress and apoptosis in podocytes. Cell Calcium 2011; 50: 523-529.
26. Kestilä M, Lenkkeri U, Männikkö M, et al. Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome. Mol Cell 1998; 1: 575-582.
27. Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nature Genet 2000; 24: 349-354.
28. Putaala H, Soininen R, Kilpeläinen P, Wartiovaara J, Tryggvason K. The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. Hum Mol Genet 2001; 10: 1-8.
29. Roselli S, Heidet L, Sich M, et al. Early glomerular filtration defect and severe renal disease in podocin-deficient mice. Mol Cell Biol 2004; 24: 550-560.
30. Doyonnas R, Kershaw DB, Duhme C, et al. Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med 2001; 194: 13-27.
31. Kaplan JM, Kim SH, North KN, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24: 251-256.
32. Michaud JL, Lemieux LI, Dubé M, Vanderhyden BC, Robertson SJ, Kennedy CR. Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant alpha-actinin-4. J Am Soc Nephrol 2003; 14: 1200-1211.
33. Kos CH, Le TC, Sinha S, et al. Mice deficient in alphaactinin-4 have severe glomerular disease. J Clin Invest 2003; 111: 1683-1690.
34. Shih NY, Li J, Karpitskii V, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999; 286: 312-315.
35. Kim JM, Wu H, Green G, et al. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 2003; 300: 1298-1300.
36. Huber TB, Kwoh C, Wu H, et al. Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin. J Clin Invest 2006; 116: 1337-1345.
37. Winn MP, Conlon PJ, Lynn KL, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308: 1801-1804.
38. Schlöndorff J, Del Camino D, Carrasquillo R, Lacey V, Pollak MR. TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFATdependent transcription. Am J Physiol Cell Physiol 2009; 296: C558-569.
39. Boyer O, Benoit G, Gribouval O, et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22: 239-245.
40. Akilesh S, Suleiman H, Yu H, et al. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J Clin Invest 2011; 121: 4127-4137.
41. Mele C, Iatropoulos P, Donadelli R, et al. MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med 2011; 365: 295-306.
42. Heng YW, Koh CG. Actin cytoskeleton dynamics and the cell division cycle. Int J Biochem Cell Biol 2010; 42: 1622-1633.
43. Buttitta LA, Edgar BA Mechanisms controlling cell cycle exit upon terminal differentiation. Curr Opin Cell Biol 2007; 19: 697-704.
44. Crescenzi M, Soddu S, Tato F. Mitotic cycle reactivation in terminally differentiated cells by adenovirus infection. J Cell Physiol 1995; 162: 26-35.
45. Banerjee NS, Genovese NJ, Noya F, et al. Conditionally activated E7 proteins of high-risk and low-risk human papillomaviruses induce S phase in postmitotic, differentiated human keratinocytes. J Virol 2006; 80: 6517-6524.
46. Latella L, Sacco A, Pajalunga D, et al. Reconstitution of cyclin D1-associated kinase activity drives terminally differentiated cells into the cell cycle. Mol Cell Biol 2001; 21: 5631-5643.
47. Campa VM, Gutierrez-Lanza R, Cerignoli F, et al. Notch activates cell cycle reentry and progression in quiescent cardiomyocytes. J Cell Biol 2008; 183: 129-141.
48. Smith DS, Leone G, DeGregori J, et al. Induction of DNA replication in adult rat neurons by deregulation of the retinoblastoma/E2F G1 cell cycle pathway. Cell Growth Differ 2000; 11: 625-633.
49. Herrup K, Yang Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat Rev Neurosci 2007; 8: 368-378.
50. Yurov YB, Vorsanova SG, Iourov IY. The DNA replication stress hypothesis of Alzheimer's disease. ScientificWorldJournal 2011; 11: 2602-2612.
51. Arendt T. Cell cycle activation and aneuploid neurons in Alzheimer's disease. Mol Neurobiol 2012; 46: 125-135.
52. Nagy Z, Esiri M. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol (Berl) 1997; 94: 6-15.
53. Busser J, Geldmacher DS. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 1998; 18: 2801-2807.
54. Arendt T, Holzer M, Gärtner U. Neuronal expression of cyclin dependent kinase inhibitors of the INK4 family in Alzheimer's disease. J Neural Transm 1998; 105: 949-960.
55. McShea A, Harris PL, Webster KR, Wahl AF, Smith MA. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 1997; 150: 1933-1939.
56. Ogawa O, Zhu X, Lee HG, et al. Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe? Acta Neuropathologica 2003; 105: 524-528.
57. Iqbal K, Tellez-Nagel I, Grundke-Iqbal I. Protein abnormalities in Huntington's chorea. Brain Res 1974; 76: 178-184.
58. Ranganathan S, Bowser R. Alterations in G(1) to S phase cell-cycle regulators during amyotrophic lateral sclerosis. Am J Pathol 2003; 162: 823-835.
59. Yang Y, Herrup K. Loss of neuronal cell cycle control in ataxia-telangiectasia: a unified disease mechanism. J Neurosci 2005; 25: 2522-2529.
60. Hoglinger G, Höglinger GU, Breunig JJ, et al. The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci USA 2007; 104: 3585-3590.
61. Love S. Neuronal expression of cell cycle-related proteins after brain ischaemia in man. Neurosci Lett 2003; 353: 29-32.
62. Jordan-Sciutto KL, Wang G, Murphey-Corb M, Wiley CA. Cell cycle proteins exhibit altered expression patterns in lentiviral-associated encephalitis. J Neurosci 2002; 22: 2185-2195.
63. Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ 2008; 15: 1153-1162.
64. Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death and Differ 2012; 19: 107-120.
65. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001; 4: 303-313.
66. He QY, Liang YY, Wang DS, Li DD. Characteristics of mitotic cell death induced by enediyne antibiotic lidamycin in human epithelial tumor cells. Int J Oncol 2002; 20: 261-266.
67. Chang BD, Broude EV, Dokmanovic M, et al. A senescencelike phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999; 59: 3761-3767.
68. Barisoni L, Mokrzycki M, Sablay L, Nagata M, Yamase H, Mundel P. Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 2000; 58: 137-143.
69. Wang S, Kim JH, Moon KC, Hong HK, Lee HS. Cell-cycle mechanisms involved in podocyte proliferation in cellular lesion of focal segmental glomerulosclerosis. Am J Kidney Dis 2004; 43: 19-27.
70. Srivastava T, Garola RE, Whiting JM, Alon US. Cell-cycle regulatory proteins in podocyte cell in idiopathic nephrotic syndrome of childhood. Kidney Int 2003; 63: 1374-1381.
71. Shankland SJ, Floege J, Thomas SE, et al. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int 1997; 52: 404-413.
72. Hoshi S, Shu Y, Yoshida F, et al. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest 2002; 82: 25-35.
73. Nitta K, Horita S, Honda K, et al. Glomerular expression of cell-cycle-regulatory proteins in human crescentic glomerulonephritis. Virchows Arch 1999; 435: 422-427.
74. Petermann AT, Hiromura K, Blonski M, et al. Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 2002; 61: 40-50.
75. Lasagni L, Ballerini L, Angelotti ML, et al. Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem Cells 2010; 28: 1674-1685.
76. Neef R, Klein UR, Kopajtich R, Barr FA. Cooperation between mitotic kinesins controls the late stages of cytokinesis. Curr Biol 2006; 16: 301-307.
77. Niranjan T, Bielesz B, Gruenwald A, et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 2008; 14: 290-298.
78. Murea M, Park JK, Sharma S, et al. Expression of Notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function. Kidney Int 2010; 78: 514-522.
79. Kriz W, Hähnel B, Rösener S, et al. Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. Kidney Int 1995; 48: 1435-1450.
80. Sasaki T, Hatta H, Osawa G. Cytokines and podocyte injury: the mechanism of fibroblast growth factor 2-induced podocyte injury. Nephrol Dial Transplant 1999; 14: 33-34.
81. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 2002; 13: 3005-3015.
82. Hugo C, Nangaku M, Shankland SJ, et al. The plasma membrane-actin linking protein, ezrin, is a glomerular epithelial cell marker in glomerulogenesis, in the adult kidney and in glomerular injury. Kidney Int 1998; 54: 1934-1944.
83. Shankland SJ, Floege J, Thomas SE, et al. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: Potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int 1997; 52: 404-413.
84. Hiromura K, Haseley LA, Zhang P, et al. Podocyte expression of the CDK-inhibitor p57 during development and disease. Kidney Int 2001; 60: 2235-2246.
85. Tenschert S, Elger M, Lemley KV. Glomerular hypertrophy after subtotal nephrectomy: Relationship to early glomerular injury. Virchows Arch 1995; 426: 509-517.
86. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005; 6: 1733-1741.
87. Bariéty J, Nochy D, Mandet C, Jacquot C, Glotz D, Meyrier A. Podocytes undergo phenotypic changes and express macrophagic-associated markers in idiopathic collapsing glomerulopathy. Kidney Int 1998; 53: 918-925.
88. Nagata M, Yamaguchi Y, Komatsu Y, Ito K. Mitosis and the presence of binucleate cells among glomerular podocytes in diseased human kidneys. Nephron 1995; 70: 68-71.
89. Olsen S. Extracapillary glomerulonephritis: A semiquantitative light microscopical study of 59 patients. Acta Pathol Microbiol Scand Suppl 1974; 249: 7-19.
90. Spear G. The proximal tubule and the podocyte in cystinosis. Nephron 1973; 10: 57-60.
91. Hotta O, Inoue CN, Miyabayashi S, Furuta T, Takeuchi A, Taguma Y. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int 2001; 59: 1236-1243.
92. Chandra M, Stokes MB, Kaskel F. Multinucleated podocytes: a diagnostic clue to cystinosis. Kidney Int 2010; 78: 1052.
93. Shkreli M, Sarin KY, Pech MF, et al. Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. Nat Med 2011; 18: 111-119.
94. Hara M, Yanagihara T, Kihara I. Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron 2001; 89: 342-347.
95. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003; 285: F40-F48.
96. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol Renal Physiol 1985; 249: F324-F337.
97. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85-93.
98. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 2012; 8: 293-300.
99. Fukuda A, Wickman LT, Venkatareddy MP, et al. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int 2012; 81: 40-55.
100. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-296.
101. Macconi D, Sangalli F, Bonomelli M, et al. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Am J Pathol 2009; 174: 797-807.
102. Gagliardini E, Corna D, Zoja C, et al. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 2009; 297: F1448-F1456.
103. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75.
104. Ruggenenti P, Perna A, Benini R, et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 1999; 10: 997-1006.
105. Sagrinati C, Netti GS, Mazzinghi B, et al. Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 2006; 17: 2443-2456.
106. Ronconi E, Sagrinati C, Angelotti ML, et al. Regeneration of glomerular podocytes by human renal progenitors. J Am Soc Nephrol 2009; 20: 322-332.
107. Lasagni L, Romagnani P. Glomerular epithelial stem cells: the good, the bad, and the ugly. J Am Soc Nephrol 2010; 21: 1612-1619.
108. Bariety J, Mandet C, Hill GS, Bruneval P. Parietal podocytes in normal human glomeruli. J Am Soc Nephrol 2006; 17: 2770-2780.
109. Appel D, Kershaw DB, Smeets B, et al. Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol 2009; 20: 333-343.
110. Smeets B, Angelotti ML, Rizzo P, et al. Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J Am Soc Nephrol 2009; 20: 2593-2603.
111. Grouls S, Iglesias DM, Wentzensen N, et al. Lineage specification of parietal epithelial cells requires β-catenin/Wnt signaling. J Am Soc Nephrol 2012; 23: 63-72.
112. Kato H, Gruenwald A, Suh JH, et al. Wnt/β-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem 2011; 286: 26003-26015.